This study tackles the development of morin hydrate-loaded Phyto-Emulsomes (MH-EMs) using β-sitosterol as a ‘heart-friendly’ alternative to cholesterol for curing leukemia. β-sitosterol was isolated from the aerial parts of C. pallescens Delile (Compositae). Phyto-Emulsomes were prepared using different ratios of glyceryl monostearate (GMS), phospholipon 80H (P80H) and ß-sitosterol (SS), then, their size, entrapment efficiency, and drug release were evaluated. Among the prepared formulae, MH-EM5 composed of GMS: P80H: SS (2:0.5:0.5) had the highest drug release efficiency (RE = 82.28 ± 1.96%) and the smallest particle size (271.7 ± 4.86 nm) with a uniform distribution. MH-EM5 was subjected to characterization including the micro-morphological examination using TEM, thermal analysis, in addition to biological evaluation. The biostability of MH-EM5 in serum and bile salts was proved. The potential cytotoxicity of the free drug, MH-EM5 and its corresponding unmedicated formulation against normal oral epithelial cell and acute monocytic leukemia was studied. The results showed a negligible cytotoxicity in normal cells for all tested samples, while, cancer cells had a significant decrease in the cell viability in case of the selected formula (MH-EM5) compared to the corresponding unmedicated one as well as the free drug, at different concentrations up to 300 μg/ml. Also, the oral bioavailability study proved the significant increase of all measured pharmacokinetic parameters, after a single oral administration of MH-EM5 compared to the free drug suspension. Regarding these findings, phyto-emulsomes can be considered as a safe and promising nanometric delivery system for the oral administration of morin hydrate due to the enhancement of its solubility, oral bioavailability and antitumor efficacy.
Kamel, R., Abousamra, M.M., Afifi, S.M., Galal, A.F. (2022). Phyto-emulsomes as a novel nano-carrier for morine hydrate to combat leukemia: In vitro and pharmacokinetic study. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 75, 1-11 [10.1016/j.jddst.2022.103700].
Phyto-emulsomes as a novel nano-carrier for morine hydrate to combat leukemia: In vitro and pharmacokinetic study
Afifi S. M.;
2022
Abstract
This study tackles the development of morin hydrate-loaded Phyto-Emulsomes (MH-EMs) using β-sitosterol as a ‘heart-friendly’ alternative to cholesterol for curing leukemia. β-sitosterol was isolated from the aerial parts of C. pallescens Delile (Compositae). Phyto-Emulsomes were prepared using different ratios of glyceryl monostearate (GMS), phospholipon 80H (P80H) and ß-sitosterol (SS), then, their size, entrapment efficiency, and drug release were evaluated. Among the prepared formulae, MH-EM5 composed of GMS: P80H: SS (2:0.5:0.5) had the highest drug release efficiency (RE = 82.28 ± 1.96%) and the smallest particle size (271.7 ± 4.86 nm) with a uniform distribution. MH-EM5 was subjected to characterization including the micro-morphological examination using TEM, thermal analysis, in addition to biological evaluation. The biostability of MH-EM5 in serum and bile salts was proved. The potential cytotoxicity of the free drug, MH-EM5 and its corresponding unmedicated formulation against normal oral epithelial cell and acute monocytic leukemia was studied. The results showed a negligible cytotoxicity in normal cells for all tested samples, while, cancer cells had a significant decrease in the cell viability in case of the selected formula (MH-EM5) compared to the corresponding unmedicated one as well as the free drug, at different concentrations up to 300 μg/ml. Also, the oral bioavailability study proved the significant increase of all measured pharmacokinetic parameters, after a single oral administration of MH-EM5 compared to the free drug suspension. Regarding these findings, phyto-emulsomes can be considered as a safe and promising nanometric delivery system for the oral administration of morin hydrate due to the enhancement of its solubility, oral bioavailability and antitumor efficacy.| File | Dimensione | Formato | |
|---|---|---|---|
|
accepted manuscript (1).pdf
Open Access dal 14/08/2023
Tipo:
Postprint / Author's Accepted Manuscript (AAM) - versione accettata per la pubblicazione dopo la peer-review
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
1.49 MB
Formato
Adobe PDF
|
1.49 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


